Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Curr Alzheimer Res. 2010 Feb;7(1):56-66. doi: 10.2174/156720510790274446.
New in vivo amyloid PET imaging tracers, such as (11)C-PIB, provide possibilities to deeper understand the underlying pathological processes in Alzheimer's disease (AD). In this study we investigated how (11)C-PIB retention is related to cerebral glucose metabolism, episodic memory and CSF biomarkers.
Thirty-seven patients with mild AD and 21 patients with mild cognitive impairment (MCI) underwent PET examinations with the amyloid tracer (11)C-PIB, (18)F-FDG for measurement of regional cerebral metabolic rate of glucose (rCMRglc), assessment of episodic memory and assay of cerebral spinal fluid (CSF) levels of amyloid-beta (Abeta(1-42)), total tau and phosphorylated tau respectively. Analyses were performed using Statistical Parametric Mapping (SPM) and regions of interest (ROIs).
Pooled data from AD and MCI patients showed strong correlations between (11)C-PIB retention, levels of CSF biomarkers (especially Abeta(1-42)), rCMRglc and episodic memory. Analysis of the MCI group alone revealed significant correlations between (11)C-PIB retention and CSF biomarkers and between CSF biomarkers and episodic memory respectively. A strong correlation was observed in the AD group between rCMRglc and episodic memory as well as a significant correlation between (11)C-PIB retention and rCMRglc in some cortical regions. Regional differences were observed as sign for changes in temporal patterns across brain regions.
A complex pattern was observed between pathological and functional markers with respect to disease stage (MCI versus AD) and brain regions. Regional differences over time were evident during disease progression. (11)C-PIB PET and CSF Abeta(42) allowed detection of prodromal stages of AD. Amyloid imaging is useful for early diagnosis and evaluation of new therapeutic interventions in AD.
新型体内淀粉样蛋白 PET 成像示踪剂,如(11)C-PIB,为深入了解阿尔茨海默病(AD)的潜在病理过程提供了可能。在这项研究中,我们研究了(11)C-PIB 保留与脑葡萄糖代谢、情景记忆和 CSF 生物标志物的关系。
37 例轻度 AD 患者和 21 例轻度认知障碍(MCI)患者接受了淀粉样蛋白示踪剂(11)C-PIB、(18)F-FDG 的 PET 检查,用于测量局部脑葡萄糖代谢率(rCMRglc)、评估情景记忆和检测脑脊液(CSF)中淀粉样蛋白-β(Abeta(1-42))、总tau 和磷酸化 tau 的水平。分析采用统计参数映射(SPM)和感兴趣区(ROI)进行。
AD 和 MCI 患者的合并数据显示,(11)C-PIB 保留与 CSF 生物标志物(尤其是 Abeta(1-42))、rCMRglc 和情景记忆之间存在强烈相关性。对 MCI 组的单独分析显示,(11)C-PIB 保留与 CSF 生物标志物之间以及 CSF 生物标志物与情景记忆之间分别存在显著相关性。AD 组中 rCMRglc 与情景记忆之间存在很强的相关性,以及(11)C-PIB 保留与某些皮质区域 rCMRglc 之间存在显著相关性。在疾病进展过程中观察到区域差异,表明脑区之间的时间模式发生了变化。
在疾病阶段(MCI 与 AD)和脑区方面,病理和功能标志物之间观察到复杂的模式。在疾病进展过程中,随着时间的推移,区域差异明显。(11)C-PIB PET 和 CSF Abeta(42)可检测 AD 的前驱期。淀粉样蛋白成像对 AD 的早期诊断和新的治疗干预评估有用。